Cargando…
Nintedanib—A case of treating concurrent idiopathic pulmonary fibrosis and non‐small cell lung cancer
Treating advanced lung cancer in patients with pulmonary fibrosis can be challenging due to increased risks of drug‐induced and radiation‐induced pneumonitis. We present the case of a 78‐year‐old female with stage IIIB lung adenocarcinoma and idiopathic pulmonary fibrosis (IPF). Following partial re...
Autores principales: | Dabholkar, Shakti, Gao, Bo, Chuong, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756078/ https://www.ncbi.nlm.nih.gov/pubmed/35059200 http://dx.doi.org/10.1002/rcr2.902 |
Ejemplares similares
-
Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018) -
Remarkable response of non‐small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis
por: Kai, Yoshiro, et al.
Publicado: (2021) -
Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017) -
Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018) -
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)